story of the week
Efficacy and Safety of SGLT2 Inhibitors With and Without GLP-1 Receptor Agonists
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
Lancet Diabetes Endocrinol 2024 Jul 08;[EPub Ahead of Print], EM Apperloo, BL Neuen, RA Fletcher, N Jongs, SD Anker, DL Bhatt, J Butler, DZI Cherney, WG Herrington, SE Inzucchi, MJ Jardine, CC Liu, KW Mahaffey, DK McGuire, JJV McMurray, B Neal, M Packer, V Perkovic, MS Sabatine, SD Solomon, N Staplin, M Szarek, M Vaduganathan, C Wanner, DC Wheeler, SD Wiviott, F Zannad, HJL HeerspinkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.